PubMed:33115285 JSONTXT

{"project":"Zierdiyeerkenaili_800_3","denotations":[{"id":"T10","span":{"begin":38,"end":49},"obj":"CI"},{"id":"T19","span":{"begin":465,"end":474},"obj":"DP"},{"id":"T20","span":{"begin":126,"end":135},"obj":"DP"},{"id":"T21","span":{"begin":835,"end":844},"obj":"DP"},{"id":"T22","span":{"begin":221,"end":230},"obj":"DP"},{"id":"T23","span":{"begin":391,"end":400},"obj":"DP"},{"id":"T24","span":{"begin":549,"end":558},"obj":"DP"},{"id":"T25","span":{"begin":1087,"end":1096},"obj":"DP"},{"id":"T26","span":{"begin":1266,"end":1275},"obj":"DP"},{"id":"T8","span":{"begin":24,"end":34},"obj":"CI"},{"id":"T9","span":{"begin":262,"end":272},"obj":"CI"},{"id":"T27","span":{"begin":335,"end":345},"obj":"CI"},{"id":"T28","span":{"begin":648,"end":658},"obj":"CI"},{"id":"T29","span":{"begin":1023,"end":1033},"obj":"CI"},{"id":"T30","span":{"begin":350,"end":361},"obj":"CI"},{"id":"T31","span":{"begin":704,"end":715},"obj":"CI"},{"id":"T32","span":{"begin":1045,"end":1056},"obj":"CI"}],"text":"A Randomized Controlled Ixekizumab Vs Secukinumab Trial to Study the Impact on Sexual Activity in Adult Patients with Genital Psoriasis.\nIntroduction: There is limited data on the effects of biologic therapies on genital psoriasis and sexual activity. Recently, Ixekizumab was reported to be effective. Aim: To compare the efficacy of ixekizumab and secukinumab for the treatment of genital psoriasis and sexual inadequacy in adult patients with moderate-to-severe psoriasis. Patients and methods: We assessed adult patients with moderate-to-severe psoriasis having genital involvement. They were randomly assigned in a 1:1 ratio to receive either ixekizumab (80 mg/2 weeks after 160-mg initial dose) or secukinumab (300 mg subcutaneous injection at Weeks 0, 1, 2, 3, and 4 then every 4 weeks). The severity was assessed using Genital Psoriasis Symptoms Scale (GPSS), and impact on sexual health by evaluating the Massachusetts General Hospital-Sexual Functioning Questionnaire (MGH-SFQ). Results: Twenty eight patients on ixekizumab, and 26 on secukinumab showed improvement in genital psoriasis symptoms, beginning week 2 (GPSS total and individual items), and from week 4 onwards, improvement in sexual activity was seen with both drugs. Conclusion: Both genital psoriasis symptoms and impact on sexual activity improved rapidly and significantly with both the IL-17 inhibitors. Limitations included small number of patients and lack of follow-up period."}

{"project":"yaoziqian_800_3","denotations":[{"id":"T1","span":{"begin":24,"end":34},"obj":"CI"},{"id":"T10","span":{"begin":704,"end":715},"obj":"CI"},{"id":"T11","span":{"begin":1023,"end":1033},"obj":"CI"},{"id":"T12","span":{"begin":1045,"end":1056},"obj":"CI"},{"id":"T15","span":{"begin":549,"end":558},"obj":"DP"},{"id":"T18","span":{"begin":465,"end":474},"obj":"DP"},{"id":"T19","span":{"begin":126,"end":135},"obj":"DP"},{"id":"T2","span":{"begin":38,"end":49},"obj":"CI"},{"id":"T20","span":{"begin":835,"end":844},"obj":"DP"},{"id":"T21","span":{"begin":221,"end":230},"obj":"DP"},{"id":"T22","span":{"begin":391,"end":400},"obj":"DP"},{"id":"T23","span":{"begin":1087,"end":1096},"obj":"DP"},{"id":"T24","span":{"begin":1266,"end":1275},"obj":"DP"},{"id":"T5","span":{"begin":262,"end":272},"obj":"CI"},{"id":"T6","span":{"begin":335,"end":345},"obj":"CI"},{"id":"T7","span":{"begin":350,"end":361},"obj":"CI"},{"id":"T9","span":{"begin":648,"end":658},"obj":"CI"}],"text":"A Randomized Controlled Ixekizumab Vs Secukinumab Trial to Study the Impact on Sexual Activity in Adult Patients with Genital Psoriasis.\nIntroduction: There is limited data on the effects of biologic therapies on genital psoriasis and sexual activity. Recently, Ixekizumab was reported to be effective. Aim: To compare the efficacy of ixekizumab and secukinumab for the treatment of genital psoriasis and sexual inadequacy in adult patients with moderate-to-severe psoriasis. Patients and methods: We assessed adult patients with moderate-to-severe psoriasis having genital involvement. They were randomly assigned in a 1:1 ratio to receive either ixekizumab (80 mg/2 weeks after 160-mg initial dose) or secukinumab (300 mg subcutaneous injection at Weeks 0, 1, 2, 3, and 4 then every 4 weeks). The severity was assessed using Genital Psoriasis Symptoms Scale (GPSS), and impact on sexual health by evaluating the Massachusetts General Hospital-Sexual Functioning Questionnaire (MGH-SFQ). Results: Twenty eight patients on ixekizumab, and 26 on secukinumab showed improvement in genital psoriasis symptoms, beginning week 2 (GPSS total and individual items), and from week 4 onwards, improvement in sexual activity was seen with both drugs. Conclusion: Both genital psoriasis symptoms and impact on sexual activity improved rapidly and significantly with both the IL-17 inhibitors. Limitations included small number of patients and lack of follow-up period."}